Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Top Analyst Reports for UnitedHealth, Bank of America & SAP

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans?

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging